MedTrace Logo

A Phase III Study of A01016 in Subjects With Symptomatic Vitreomacular Adhesion

NCT01889251 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 251

Last updated 2015-11-30

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the superiority regarding vitreomacular adhesion (VMA) resolution of a single intravitreal injection of A01016 (Ocriplasmin) compared to sham-injection in subjects with symptomatic VMA.

Conditions

  • Symptomatic Vitreomacular Adhesion

Interventions

DRUG

Ocriplasmin

DRUG

Sham injection

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Group Manager, Clinical Development · Alcon Japan, Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2014-09-30
Completion
2014-09-30

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01889251 on ClinicalTrials.gov